RR

Rebala Rupakala

Active Director Director DIN 07623584
DIN 07623584 First appointment Oct 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 3 active board seats
Total affiliations 3 Since Oct 2016
Shareholding value •••• Premium profile

About Rebala Rupakala

Data last updated:

Rebala Rupakala is a Director at Hatri Pharma Private Limited (since 2017), Director at Emr Laboratories Private Limited (since 2016) and Director at Reddys Therapeutics Private Limited (since 2016). The companies operate in Pharma and Healthcare. The 3 current companies with reported revenue have a combined latest revenue of ₹89 Lakh; the largest is Hatri Pharma Private Limited at ₹71.7 Lakh (FY 2025).

DIN 07623584
Primary Designation Director
Industry Pharma
First Appointment 20 Oct 2016
Oldest Company Age 16 yrs
Largest company Hatri Pharma Private Limited · ₹71.7 Lakh (FY 2025)
Combined revenue ₹89 Lakh across 3 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Hatri Pharma Private Limited U24232TS2010PTC205106
Director30 Oct 20172010₹71.7 Lakh (FY 2025)Active
Emr Laboratories Private Limited U24304AP2016PTC104301
Director20 Oct 20162016₹11.5 Lakh (FY 2023)Active
Reddys Therapeutics Private Limited U24290AP2016PTC104315
Director21 Oct 20162016₹5.9 Lakh (FY 2022)Active

Directorship timeline

Open interactive timeline →
Hatri Pharma Private Limited
Reddys Therapeutics Private Limited
Emr Laboratories Private Limited
Premium access

Shareholding and investment profile for Rebala Rupakala

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rebala Rupakala

Rebala Rupakala currently holds 3 directorships: Hatri Pharma Private Limited (Director, since 30 Oct 2017, revenue ₹71.7 Lakh (FY 2025)); Emr Laboratories Private Limited (Director, since 20 Oct 2016, revenue ₹11.5 Lakh (FY 2023)); Reddys Therapeutics Private Limited (Director, since 21 Oct 2016, revenue ₹5.9 Lakh (FY 2022)).

Rebala Rupakala was first appointed on 20 Oct 2016 as Director at Emr Laboratories Private Limited. The most recent appointment on record is 30 Oct 2017 at Hatri Pharma Private Limited.

The 3 current companies of Rebala Rupakala that report revenue have a combined latest revenue of ₹89 Lakh: Hatri Pharma Private Limited ₹71.7 Lakh (FY 2025); Emr Laboratories Private Limited ₹11.5 Lakh (FY 2023); Reddys Therapeutics Private Limited ₹5.9 Lakh (FY 2022).

The current boards of Rebala Rupakala's companies include Mohan Reddy Enaganuri (Hatri Pharma Private Limited), Sumalatha Ambarapu (Hatri Pharma Private Limited), Mohan Sai Sundar Reddy Devarapalli (Reddys Therapeutics Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available